Meeting
2023 ASCO Annual Meeting
Predictive biomarkers of benefit to axitinib plus avelumab in patients with recurrent/metastatic adenoid cystic carcinoma (R/M ACC).
Authors
Camilla Oliveira Hoff
The University of Texas MD Anderson Cancer Center, Houston, TX
Camilla Oliveira Hoff , Daniel McGrail , Simon Heeke , Luana Guimaraes de Sousa , Kaiyi Li , Diana Bell , Yoshitsugu Mitani , Mario L. Marques-Piubelli , Maria Angelica Cortez , Shiaw-Yih Lin , Yasir Y Elamin , Adel K. El-Naggar , Renata Ferrarotto
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Other Head and Neck Cancer (Salivary, Thyroid)
Clinical Trial Registration Number
NCT03990571
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 6096)
DOI
10.1200/JCO.2023.41.16_suppl.6096
Abstract #
6096
Poster Bd #
88
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A phase 2 clinical trial of axitinib and avelumab in patients with recurrent/metastatic adenoid cystic carcinoma (ACC).
First Author: Renata Ferrarotto
Poster
2023 ASCO Annual Meeting
A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair–proficient (MMR-P) recurrent or persistent endometrial cancer (EC).
First Author: Elizabeth Katherine Lee
Poster
2021 ASCO Annual Meeting
A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient (MMR-P) recurrent or persistent endometrial cancer (EC).
First Author: Elizabeth Katherine Lee
Poster
2020 ASCO Virtual Scientific Program
SPRING: A Worldwide Innovative Network (WIN) Consortium phase I study of triple therapy (avelumab, axitinib, and palbociclib) in advanced non-small cell lung cancer (NSCLC) with genomic and transcriptomic correlates.
First Author: Benjamin Maurice Solomon